Peptide · Growth-Hormone Support
Tesamorelin / Ipamorelin
Tesamorelin's visceral-fat-tuned GHRH signal paired with Ipamorelin's clean, selective release trigger — two peptides firing one fuller, more natural GH pulse.
Available by consultation
What it is
Visceral Fat + Recovery Stack
Tesamorelin / Ipamorelin is a two-peptide growth-hormone protocol that pairs complementary halves of the same axis. Tesamorelin is a stabilized GHRH analog — resistant to the rapid enzymatic breakdown that limits native GHRH, and the GHRH peptide most closely associated with research on visceral adipose tissue, the deep abdominal fat stored around the organs rather than the fat you can pinch. Ipamorelin is a selective GH secretagogue, a ghrelin-receptor agonist that triggers a discrete GH pulse through a separate receptor without meaningfully stirring cortisol or prolactin. Used together under a provider's direction, the pairing is intended to combine Tesamorelin's deep-abdominal, metabolic emphasis with a fuller, more natural GH surge — extending the emphasis toward the lean-mass and recovery signals a GHRH analog alone drives less directly. These are compounded therapies and are not FDA-approved products.
Growth hormone is released in nighttime pulses. This stack works on both halves of that pulse — the strength of the GHRH signal telling the pituitary to produce GH, and the ghrelin-receptor trigger that fires it — with the GHRH half chosen specifically for its visceral-fat association.
Tesamorelin sends the durable, visceral-tuned signal
Native GHRH degrades within minutes; Tesamorelin's stabilizing modification resists that breakdown, so it activates pituitary GHRH receptors with a more sustained signal — the GHRH analog whose research has centered on the deep abdominal fat depot rather than surface tissue.
Ipamorelin fires the selective pulse
Acting on the separate ghrelin / GH-secretagogue receptor, Ipamorelin prompts a discrete burst of stored GH. Its draw is selectivity — unlike broader older secretagogues, it is designed to do little to cortisol, prolactin, or appetite-driving signals. This is the second receptor that Tesamorelin's GHRH signal alone never engages.
Push and pull, one fuller pulse
A raised GHRH tone from Tesamorelin plus Ipamorelin's clean release trigger is intended to produce a fuller, more physiologic pulse than Tesamorelin alone — carrying the visceral-fat orientation while adding the lean-mass and recovery emphasis associated with a well-fired GH pulse, and preserving the feedback loops that keep GH in a natural rhythm.
Candidacy
A considered fit, not a funnel.
This pairing suits adults drawn to Tesamorelin's deep-abdominal, metabolic focus who also value the recovery and lean-tissue side of a fuller GH pulse — people already eating well and training, sometimes already on a GLP-1, who carry stubborn deep-belly fullness and want to work with their own endocrine rhythm rather than replace the hormone. It fits those willing to inject nightly and titrate to IGF-1 feedback, and it is prescribed only when a licensed provider judges it clinically appropriate for you.
- Adults with disproportionate deep abdominal fullness who also want the recovery and lean-tissue side of a fuller GH pulse
- Those drawn to Tesamorelin's visceral-fat emphasis but wanting more than a single GHRH lever
- People comfortable with a nightly bedtime subcutaneous routine and periodic IGF-1 labs
- Anyone pregnant, trying to conceive, or breastfeeding
- A history of pituitary or hypothalamic tumor, surgery, or radiation, or active malignancy given GH/IGF-1's growth signaling
- People already on growth-hormone therapy, or with uncontrolled diabetes or proliferative diabetic retinopathy
Expected Timeline
What to expect
Because the largest GH pulse rides on slow-wave sleep, this stack is timed to reinforce that window — and because visceral fat is a slow-moving depot, the metabolic side rewards patience even as recovery and sleep signals may surface sooner.
- 01
Weeks 1-2
Onboarding & bedtime dosing
After provider review and baseline labs (often including IGF-1), you begin a nightly subcutaneous dose at bedtime on an empty stomach — timing that aligns both peptides with your deepest sleep. Early days are mostly about routine and tolerability; sleep quality is often what people report noticing first.
- 02
Weeks 3-8
Adaptation
The body settles into the reinforced GH rhythm. Recovery, training capacity, and sleep signals tend to emerge before any visceral-fat change, which is still building beneath the surface. Providers commonly cycle the Ipamorelin dosing to help keep the ghrelin receptor responsive.
- 03
Months 3-6
Visceral response & titration
This is the window in which deep-abdominal and waistline shifts more often become noticeable for those who respond. An IGF-1 draw helps your provider confirm you are in a sensible physiologic range and fine-tune dose, timing, and cycling.
Response varies with age, sleep, training, and baseline GH output; your provider adjusts dose, timing, cycling, or duration — or stops therapy — based on your labs and results. Individual outcomes are not guaranteed.
The Science
Why clinicians reach for it.
Interest in this pairing comes from joining two well-characterized peptide classes — a visceral-fat-associated GHRH analog and a selective GH secretagogue — so their mechanisms reinforce one another at the pituitary rather than duplicating each other.
Two receptors, one pulse
GHRH analogs like Tesamorelin and ghrelin-receptor agonists like Ipamorelin act on distinct pituitary pathways. Combining a GHRH analog with a secretagogue has long been explored on the rationale that their effect on GH release together tends to exceed what either delivers alone.
A visceral-fat-associated backbone
Among GH-axis peptides, Tesamorelin carries the most specific body of research around excess visceral adipose tissue — which is why it, rather than a more general GHRH analog such as CJC-1295, anchors the GHRH half of this stack.
Pulsatile, not flat
Signaling the pituitary rather than administering GH directly is intended to preserve the body's pulsatile pattern and negative-feedback safeguards — an approach many clinicians consider more physiologic. These are compounded therapies and are not FDA-approved products.
Our Standard of Care
Real transformation, with a friendly team that stands by you every step.
- 01.Provider-Supervised
- Licensed providers review your health profile and guide every treatment decision. You only move forward when a plan is right for you.
- 02.Personalized Plans
- GLP-1 and peptide protocols are titrated to your biology and your goals. No one-size-fits-all, no guesswork.
- 03.We Stand By You
- From eligibility review to ongoing check-ins, our care team supports you throughout your transformation — discreet shipping and secure messaging included.
Clinical Safety
No therapy is right for everyone.
What to know
Most commonly reported effects are mild and often transient: injection-site reactions (redness, itching, or swelling), fluid retention or peripheral puffiness, joint aches or muscle pain, tingling or numbness in the hands, a brief flushing or head-rush shortly after dosing, and vivid dreams or grogginess as sleep architecture shifts. Some people notice mild hunger, reflecting Ipamorelin's ghrelin-receptor activity. Because GH activity can affect glucose handling, blood sugar and insulin sensitivity may shift and are monitored, particularly in those with diabetes or prediabetes. Report persistent joint aching, swelling, or numbness to your provider.
Contraindications
Not appropriate during pregnancy, attempts to conceive, or breastfeeding, or for anyone with active or prior malignancy given GH/IGF-1's role in cell growth, or a disrupted hypothalamic-pituitary axis (pituitary or hypothalamic tumor, surgery, radiation, or trauma). Use caution or avoid with proliferative diabetic retinopathy, uncontrolled diabetes, or concurrent growth-hormone therapy, and with any hypersensitivity to tesamorelin, ipamorelin, or mannitol. A licensed provider screens your full history and medication list before deciding whether this stack is suitable for you.
MagsRX protocols are prepared by partner compounding pharmacies in the United States. Compounding pharmacies are regulated by both state boards and the FDA and have been part of American medicine since long before mass-manufactured drugs existed. The active ingredient is prepared per your protocol — supervised by your provider — and delivered direct to your door.
Frequently Asked
Questions worth asking before you begin.
Tesamorelin on its own is a single GHRH lever — it raises the signal telling your pituitary to release GH, with research centered on visceral abdominal fat. This protocol keeps that Tesamorelin backbone and adds Ipamorelin, a selective secretagogue that fires the pulse through a separate ghrelin receptor. The intent is a fuller, more natural GH surge that carries Tesamorelin's visceral-fat focus while extending emphasis toward lean recovery and sleep.
Both pair Ipamorelin with a GHRH-type peptide, so the release trigger is the same. The difference is the GHRH half: CJC-1295 is a general long-acting GHRH analog weighted toward body composition, recovery, and sleep, while this stack uses Tesamorelin — the GHRH analog most associated with research on deep visceral fat. Choose this pairing when the deep-abdominal, metabolic emphasis matters most.
No. Both peptides signal your own pituitary to release GH in its natural pulsatile rhythm and keep your feedback loops intact — a different approach from taking growth hormone directly. It is a compounded therapy, not an FDA-approved product, prescribed only if a licensed provider judges it appropriate for you.
Explore More
Other therapies to consider.
GH SupportSermorelin
A GHRH analog that asks your own pituitary to release growth hormone on its natural nightly schedule — rather than replacing the hormone from outside.
Learn more →- GH Secretagogue Stack
Ipamorelin + CJC-1295
Two peptides, two doorways into your own growth hormone — a steady GHRH signal from CJC-1295 paired with Ipamorelin's clean release trigger, tuned to work with your nightly rhythm rather than override it.
Learn more → - Tissue Repair
BPC-157
A body-protection pentadecapeptide studied for how it may support the slow-healing places — a strained tendon, an irritable gut lining, a joint that lingers.
Learn more →
Begin
Tesamorelin / Ipamorelin begins with a short assessment.
A licensed provider reviews every order and prescribes only if it is clinically appropriate for you. Your therapy is prepared by a partner compounding pharmacy and delivered discreetly to your door.